UK regulators map a nine step export route for cell-cultivated food
The FSA and Food Standards Scotland published a nine step process map for exporting cell-cultivated products from Great Britain to non-EU markets.
The Food Standards Agency, working with Food Standards Scotland, published guidance on 12 November that sets out nine steps for exporting cell-cultivated products of animal origin from Great Britain to countries outside the European Union. The document gathers requirements from HM Revenue and Customs, the Animal and Plant Health Agency, the Department for Business, Innovation, Science and Trade and Defra into one process map, which the agency describes as an indicative overview rather than a legal guarantee.
The nine steps run from checking destination country eligibility and market access, through confirming that the Great Britain establishment and the product itself qualify under sanitary and phytosanitary rules, export health certification where the destination asks for it, and the customs declaration service, to temperature control in transit, labelling and packaging compliance, documentation and traceability, and compliance at dispatch and on arrival. The FSA is explicit about the limits: market access depends on the destination country's own law, its import conditions and the decisions of its competent authority, and the guidance does not replace existing export procedures.
"Businesses have told us that understanding the cross-government export process was a priority," said Dr Thomas Vincent, Deputy Director of Sandbox and Innovation at the Food Standards Agency, who added that the market for cell-cultivated food is growing internationally. The guidance is the latest output of the Cell-Cultivated Products Sandbox Programme that the FSA runs with Food Standards Scotland, and it is written for new companies and start-ups rather than for established exporters of animal products.
The sequencing is the interesting part. No cell-cultivated product has yet been cleared for sale as human food in Great Britain and several dossiers remain with the regulator, so the export path is being documented before the domestic market opens. The guidance also covers only non-EU destinations. Anything headed into the European Union still runs through the EU novel food procedure and a safety assessment by the European Food Safety Authority, on a slower clock.
For founders, the value of a document like this sits in the capital plan rather than in the announcement. A mapped customs and certification route means a first British plant can be underwritten partly against export revenue from markets such as Singapore, the United States or Israel while the domestic file is still pending, which changes how much capacity has to be built and when the site has to pay for itself. The practical work is unglamorous: export health certificates, cold chain records and traceability files are cheap to design into a facility and expensive to retrofit into one. Teams weighing Great Britain against EU locations now have one concrete difference to put in front of an investment committee, and investors have one more thing to ask for in diligence.
UK regulators map a nine step export route for cell-cultivated food
The Food Standards Agency and Food Standards Scotland have pulled customs, certification and cold chain requirements into a single process map for shipping cell-cultivated products of animal origin out of Great Britain.
The Food Standards Agency, working with Food Standards Scotland, published guidance on 12 November that sets out nine steps for exporting cell-cultivated products of animal origin from Great Britain to countries outside the European Union. The document gathers requirements from HM Revenue and Customs, the Animal and Plant Health Agency, the Department for Business, Innovation, Science and Trade and Defra into one process map, which the agency describes as an indicative overview rather than a legal guarantee.
The nine steps run from checking destination country eligibility and market access, through confirming that the Great Britain establishment and the product itself qualify under sanitary and phytosanitary rules, export health certification where the destination asks for it, and the customs declaration service, to temperature control in transit, labelling and packaging compliance, documentation and traceability, and compliance at dispatch and on arrival. The FSA is explicit about the limits: market access depends on the destination country's own law, its import conditions and the decisions of its competent authority, and the guidance does not replace existing export procedures.
"Businesses have told us that understanding the cross-government export process was a priority," said Dr Thomas Vincent, Deputy Director of Sandbox and Innovation at the Food Standards Agency, who added that the market for cell-cultivated food is growing internationally. The guidance is the latest output of the Cell-Cultivated Products Sandbox Programme that the FSA runs with Food Standards Scotland, and it is written for new companies and start-ups rather than for established exporters of animal products.
The sequencing is the interesting part. No cell-cultivated product has yet been cleared for sale as human food in Great Britain and several dossiers remain with the regulator, so the export path is being documented before the domestic market opens. The guidance also covers only non-EU destinations. Anything headed into the European Union still runs through the EU novel food procedure and a safety assessment by the European Food Safety Authority, on a slower clock.
For founders, the value of a document like this sits in the capital plan rather than in the announcement. A mapped customs and certification route means a first British plant can be underwritten partly against export revenue from markets such as Singapore, the United States or Israel while the domestic file is still pending, which changes how much capacity has to be built and when the site has to pay for itself. The practical work is unglamorous: export health certificates, cold chain records and traceability files are cheap to design into a facility and expensive to retrofit into one. Teams weighing Great Britain against EU locations now have one concrete difference to put in front of an investment committee, and investors have one more thing to ask for in diligence.